Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.
作者： Ronald J Bosch , Kara Bennett , Ann C Collier , Robert Zackin , Constance A Benson
DOI: 10.1097/QAI.0B013E31802C7E20
关键词:
摘要: OBJECTIVE To examine pretreatment factors associated with longer term (144 weeks) responses to antiretroviral therapy (ART). METHODS Of 1498 ART-naive subjects randomized ART regimens, including > or =3 agents, 1083 patients who had plasma HIV RNA (vRNA) levels and CD4 cell counts at baseline week 144 were analyzed. Primary evaluated count, vRNA level, gender, race, age, using multivariable Cox, log-binomial, linear regression models. RESULTS Shorter time achieving a level <50 copies/mL was lower (P < 0.001), older age = 0.007), count 0.055). After adjusting for 0.018). Greater increases from (mean 284 cells/microL) seen in younger men, blacks, higher levels; the effect of most apparent women. CONCLUSIONS Older important predictor 144; predictors copies/mL. The influence on differed between men
lww.com 
sci-hub.se 参考文章(51)
Laura M Smeaton, Victor DeGruttola, Gregory K Robbins, Robert W Shafer, ACTG (AIDS Clinical Trials Group) 384 Controlled Clinical Trials. ,vol. 22, pp. 142- 159 ,(2001) , 10.1016/S0197-2456(00)00126-4
Robert S. Hogg, Evan Wood, P. Richard Harrigan, Julio S. G. Montaner, Benita Yip, Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy Revista De Investigacion Clinica. ,vol. 56, pp. 232- 236 ,(2004)
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. The Lancet. ,vol. 362, pp. 679- 686 ,(2003) , 10.1016/S0140-6736(03)14229-8
Matthias Egger, Margaret May, Geneviève Chêne, Andrew N Phillips, Bruno Ledergerber, François Dabis, Dominique Costagliola, Antonella D'Arminio Monforte, Frank De Wolf, Peter Reiss, Jens D Lundgren, Amy C Justice, Schlomo Staszewski, Catherine Leport, Robert S Hogg, Caroline A Sabin, M John Gill, Bernd Salzberger, Jonathan AC Sterne, None, Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet. ,vol. 360, pp. 119- 129 ,(2002) , 10.1016/S0140-6736(02)09411-4
Kelly A. Gebo, Joel E. Gallant, Jeanne C. Keruly, Richard D. Moore, Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. Journal of Acquired Immune Deficiency Syndromes. ,vol. 36, pp. 1028- 1033 ,(2004) , 10.1097/00126334-200408150-00005
Maria Patrizia Carrieri, Catherine Leport, Camelia Protopopescu, Jill-Patrice Cassuto, Elisabeth Bouvet, Dominique Peyramond, Francois Raffi, Jean-Paul Moatti, Genevi??ve Che??, Bruno Spire, Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of Acquired Immune Deficiency Syndromes. ,vol. 41, pp. 477- 485 ,(2006) , 10.1097/01.QAI.0000186364.27587.0E
Richard L. Hengel, Bonnie M. Jones, M. Susan Kennedy, Marjorie R. Hubbard, J. Steven Mcdougal, Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection. AIDS Research and Human Retroviruses. ,vol. 15, pp. 435- 443 ,(1999) , 10.1089/088922299311187
Roger Paredes, Amanda Mocroft, Ole Kirk, Adriano Lazzarin, Simon E Barton, Jan Van Lunzen, Terese L Katzenstein, Francisco Antunes, Jens D Lundgren, Bonaventura Clotet, EuroSIDA Study Group, Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe: Results From the EuroSIDA Study JAMA Internal Medicine. ,vol. 160, pp. 1123- 1132 ,(2000) , 10.1001/ARCHINTE.160.8.1123
Antonia L. Moore, Ole Kirk, Anne M. Johnson, Christine Katlama, Anders Blaxhult, Manfred Dietrich, Robert Colebunders, Antonio Chiesi, Jens D. Lungren, Andrew N. Phillips, Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. Journal of Acquired Immune Deficiency Syndromes. ,vol. 32, pp. 452- 461 ,(2003) , 10.1097/00126334-200304010-00017
Steven G. Deeks, Frederick M. Hecht, Melinda Swanson, Tarek Elbeik, Richard Loftus, P. T. Cohen, Robert M. Grant, HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. ,vol. 13, ,(1999) , 10.1097/00002030-199904160-00001